An updated meta-analysis of the prognostic value of decreased E-cadherin expression in ovarian cancer

LiLi Yu; Xiaoli Hua; Yu Yang; Ke Li; Qilin Zhang; Lixiu Yu

doi:10.18632/oncotarget.20885

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

This article has been corrected. Correction in: Oncotarget. 2018; 9:20220.

An updated meta-analysis of the prognostic value of decreased E-cadherin expression in ovarian cancer

LiLi Yu, Xiaoli Hua, Yu Yang, Ke Li, Qilin Zhang and Lixiu Yu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:81176-81185. https://doi.org/10.18632/oncotarget.20885

Metrics: PDF 1743 views | HTML 2260 views | ?

Abstract

LiLi Yu1, Xiaoli Hua2, Yu Yang2, Ke Li2, Qilin Zhang2 and Lixiu Yu2

1Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China

2Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China

Correspondence to:

Lixiu Yu, email: [email protected]

Keywords: ovarian cancer, E-cadherin, prognosis, updated meta-analysis

Received: March 22, 2017 Accepted: August 26, 2017 Published: September 14, 2017

ABSTRACT

Decreased epithelial cadherin (E-cadherin) expression is hypothesized to be related to poor prognosis of ovarian cancer, but the predictive value is still inconsistent. We conducted an updated meta-analysis with a total of 16 studies enrolling 1720 patients to estimate the prognostic value of decreased E-cadherin expression in ovarian cancer. Reduced expression of E-cadherin was significantly associated to poor overall survival (HR = 1.74, 95% CI: 1.40–2.17) and progression-free survival (HR = 1.45, 95% CI: 1.12–1.86) with a large heterogeneity for overall survival. In addition, we found that decreased expression of E-cadherin was significantly correlated with International Federation of Gynecology and Obstetrics grade (HR = 3.74, 95% CI: 2.24–6.23), E-cadherin membranous (HR = 1.47, 95% CI: 1.01–2.14), pathologic grade (HR = 1.41, 95% CI: 1.01–1.97), residual tumor size (HR = 2.72, 95% CI: 1.99–3.72), and surgery (HR = 3.21, 95% CI: 1.19–8.67). Our finding suggests that decreased E-cadherin expression may be a predictor of poor ovarian cancer prognosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20885

Publication Alerts

Post-Publication Promotion

Meta-Analysis:

An updated meta-analysis of the prognostic value of decreased E-cadherin expression in ovarian cancer

Abstract